Eureka tackles major challenges for T cells in solid tumors with $45M E round, Lyell deal
Eureka is moving its TCR-mimicking antibodies forward with a new partner and new funding
Eureka is taking the next steps to bring cell therapies into solid tumors with a $45 million series E round and a new partnership with solid tumor cell therapy company Lyell.
Eureka Therapeutics Inc. and Lyell Immunopharma Inc., which led the venture round, are teaming up to develop T cell therapies against several solid tumor targets; details are undisclosed.
There are three main challenges to bringing T cell